低睾酮水平与局部前列腺癌主动监测中分级组进展的回顾性队列研究
该回顾性队列纳入2005至2024年接受主动监测的924例局部前列腺癌患者,中位随访46.1个月。
要点
- 低睾酮(≤300 ng/dL)与主动监测中GG3及以上进展风险增加相关。
- 低睾酮与GG2进展无显著关联。
- 结果在替代切点及考虑其他混杂因素后一致。
核心结论
- 低睾酮不明确关联中度进展(GG2),但可能增加高级别「极端」进展至GG3或更高疾病的风险。
研究设计与样本
- 回顾性队列研究,纳入2005至2024年参加主动监测项目的924例男性,未进展者中位随访46.1个月。
主要发现
- 924例中平均年龄63.6岁(SD 8.1),平均PSA密度0.13 ng/mL2(SD 0.14),平均基线睾酮394 ng/dL(SD 160.4)。
- 29.4%(n=272)的男性睾酮水平≤300 ng/dL。
- 低睾酮与GG2进展风险无关(HR 1.25,95%CI 0.93-1.67,P=0.13)。
- 采用替代睾酮切点及考虑其他潜在混杂因素时,结果一致。
临床怎么用
- 对主动监测的局部前列腺癌患者,基线睾酮≤300 ng/dL可能提示需更关注高级别进展风险。
局限性
- 回顾性设计,需前瞻性验证以阐明雄激素与前列腺癌进展的生物学关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Active surveillance (AS) is an increasingly used strategy for managing localized prostate cancer, yet reliable biomarkers for predicting disease progression remain limited. Low testosterone has been associated with aggressive prostate cancer features at diagnosis, but its role in Grade Group (GG) progression during AS remains unclear. Our objective was to evaluate the association between baseline serum testosterone levels and GG progression in men undergoing AS for localized prostate cancer. MATERIALS AND METHODS: We conducted a retrospective cohort study of 924 men enrolled in an AS program between 2005 and 2024, with a median follow-up of 46.1 months among those who did not progress. Serum testosterone levels were categorized as low if they met a threshold of ≤ 300 ng/dL based on guideline recommendations. Primary outcomes were biopsy progression to GG2 or "extreme" progression to GG3 or higher disease. Multivariable Cox proportional hazards models were used to assess associations between testosterone levels and progression, adjusting for age, PSA density, and biopsy tumor volume. Potential clinically significant confounding by BMI, smoking status, and ethnicity was also considered. RESULTS: Among 924 men, the mean age was 63.6 years (SD 8.1), and the mean PSA density was 0.13 ng/mL2 (SD 0.14). The average baseline testosterone was 394 ng/dL (SD 160.4), with 29.4% (n = 272) of men having a testosterone level ≤ 300 ng/dL. Low testosterone was associated with a statistically significant increased risk of GG3 progression (HR 1.61, 95% CI 1.02-2.54, P = .04). Furthermore, evidence suggested that low testosterone was not associated with risk of GG2 progression (HR 1.25, 95% CI 0.93-1.67, P = .13). Findings were consistent when employing alternative cut points for testosterone and when considering other potential confounders. CONCLUSIONS: These findings suggest that while low testosterone is not clearly associated with moderate progression (GG2), it may increase the risk of higher-grade "extreme" progression to GG3 or higher. Future studies should focus on prospective validation of our findings to elucidate the biological relationship between androgens and prostate cancer progression.
引用
- Lawen T, Garcia RS, Smith MT, et al. Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study. J Urol. 2026. PMID: 41662578. doi:10.1097/JU.0000000000004986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。